A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2019
Price : $35 *
At a glance
- Drugs Mivavotinib (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 08 Mar 2019 Status changed from not yet recruiting to recruiting.
- 04 Jan 2019 Planned initiation date changed from 31 Dec 2018 to 1 Feb 2019.
- 05 Dec 2018 New trial record